Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate selectively binds to the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from activating the receptor. This inhibition stops the cascade that leads to vasodilation and increased vascular permeability, which are responsible for the rapid edema seen in hereditary angioedema. The result is a swift reduction in swelling without affecting other kinins.

The dose of Icatibant Fresenius is determined by the prescribing clinician based on the patient’s condition, severity of the attack, and clinical guidelines. The medication is administered as a subcutaneous injection, and the prescriber decides the exact amount, frequency, and any repeat dosing required for optimal therapeutic effect.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the lack of extensive studies and consider alternative treatments when appropriate.

To request Icatibant Fresenius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assistance with import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other HAE therapies include C1‑inhibitor concentrates and kallikrein inhibitors. Icatibant acts downstream of the bradykinin pathway, offering rapid symptom relief after subcutaneous injection, while C1‑inhibitor products replace the deficient protein intravenously. Choice of therapy depends on patient preference, attack severity, and clinical response.

Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 days and return the product to refrigeration as soon as possible.

The medication is supplied as a sterile injection solution for subcutaneous use. A healthcare professional or trained patient injects the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, using a sterile needle. The injection site should be rotated for repeated doses, and the patient should be observed for any immediate adverse reactions.

The most serious risks include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, and rare cases of severe injection‑site necrosis or thrombocytopenia. Patients should be monitored closely after administration, and any signs of severe allergic response, uncontrolled swelling, or unexpected bleeding should prompt immediate medical evaluation.

Icatibant Fresenius is contraindicated in individuals with known hypersensitivity to icatibant acetate or any excipients in the formulation. It should also be avoided in patients who have experienced severe allergic reactions to other bradykinin B2 receptor antagonists. Clinicians must assess each patient’s medical history before prescribing the medication.